In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Hepa Wash reels in €3.8m in series A

This article was originally published in Clinica

Executive Summary

Liver assist device company Hepa Wash (Munich, Germany) plans to initiate clinical studies of its first-generation system after raising €3.8m ($5.6m) in its first venture financing round. The series A financing came from German investment bank KfW Bankengruppe and unnamed private investors. The Hepa Wash procedure uses a proprietary liver dialysis system, comparable to a kidney dialysis machine, which removes protein-bound toxins from the patient's blood in order to stimulate liver function. The procedure has already been evaluated in two preclinical trials. Clinical studies are expected to start in the first half of 2010. According to estimates from the World Health Organization, over 12 million people suffer from liver disease worldwide. The limited number of liver donors means that there is an urgent need for an alternative to liver transplantation to help treat patients with liver failure, according to Hepa Wash.






Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts